0576-88813233
MK 2206 dihydrochloride 是一种口服有效的 Akt 变构抑制剂,抑制 Akt1/Akt2/Akt3 的 IC50 分别为 5 nM/12 nM/65 nM。
中文别名:
(8-[4-(1-氨基环丁基)苯基]-9-苯基-2H-[1,2,4]三唑并[3,4-F][1,6]萘啶-3-酮)二盐酸盐
8-[4-(1-氨基环丁基)苯基]-9-苯基-1,2,4-噻唑并[3,4-f][1,6]萘啶-3(2H)-酮双盐酸盐
[1]. Zhao YY, et al. Effects of an oral allosteric AKT inhibitor (MK-2206) on human nasopharyngeal cancer in vitro and in vivo. Drug Des Devel Ther. 2014 Oct 10;8:1827-37.
[2]. Hirai H, et al. MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Therapy, 2010, 9(7), 1956-1967.
版权所有 Copyright(C) 2018-2024 台州市科瑞生物技术有限公司